Scalaradial, a Dialdehyde‐Containing Marine Metabolite That Causes an Unexpected Noncovalent PLA2 Inactivation

Several marine terpenoids that contain at least one reactive aldehyde group, such as manoalide and its congeners, possess interesting anti‐inflammatory activities that are mediated by the covalent inactivation of secretory phospholipase A2 (sPLA2). Scalaradial, a 1,4‐dialdehyde marine terpenoid that was isolated from the sponge Cacospongia mollior, is endowed with a relevant anti‐inflammatory profile, both in vitro and in vivo, through selective sPLA2 inhibition. Due to its peculiar dialdehyde structural feature, it has been proposed that scalaradial exerts its enzymatic inactivation by means of an irreversible covalent modification of its target. In the context of our on‐going research on anti‐PLA2 natural products and their interaction at a molecular level, we studied scalaradial in an attempt to shed more light on the molecular mechanism of its PLA2 inhibition. A detailed analysis of the reaction profile between scalaradial and bee venom PLA2, a model sPLA2 that shares a high structural homology with the human synovial enzyme, was performed by a combination of spectroscopic techniques, chemical reactions (selective modifications, biomimetic reactions), and classical protein chemistry (such as proteolytic digestion, HPLC and mass spectrometry), along with molecular modeling studies. Unexpectedly, our data clearly indicated the noncovalent forces to be the leading event in the PLA2 inactivation process; thus, the covalent modification of the enzyme emerges as only a minor side event in the ligand–enzyme interaction. The overall picture might be useful in the design of SLD analogues as new potential anti‐inflammatory compounds that target sPLA2 enzymes.

[1]  G. Cimino,et al.  Identification of an intermediate in the reaction between polygodial and methylamine in biomimetic conditions , 1984 .

[2]  L. Gomez‐Paloma,et al.  The Molecular Mechanism of Bee Venom Phospholipase A2 Inactivation by Bolinaquinone , 2006, Chembiochem : a European journal of chemical biology.

[3]  G. Cimino,et al.  Further sesterterpenes from the spongeSpongia nitens: 12-epi-scalaradial and 12,18-diepi-scalaradial , 1979, Experientia.

[4]  P. Scheuer,et al.  Manoalide, an antibiotic sesterterpenoid from the marine sponge (polejaeff) , 1980 .

[5]  D. Wilton,et al.  Inhibition of secreted phospholipases A2 by annexin V. Competition for anionic phospholipid interfaces allows an assessment of the relative interfacial affinities of secreted phospholipases A2. , 1998, Biochimica et biophysica acta.

[6]  K. Glaser,et al.  Inactivation of bee venom phospholipase A2 by manoalide. A model based on the reactivity of manoalide with amino acids and peptide sequences. , 1987, Biochemical pharmacology.

[7]  L. Gomez‐Paloma,et al.  PLA2‐mediated catalytic activation of its inhibitor 25‐acetyl‐petrosaspongiolide M: serendipitous identification of a new PLA2 suicide inhibitor , 2004, FEBS letters.

[8]  Claudio N. Cavasotto,et al.  Ligand docking and structure-based virtual screening in drug discovery. , 2007, Current topics in medicinal chemistry.

[9]  L. Parente Pros and cons of selective inhibition of cyclooxygenase-2 versus dual lipoxygenase/cyclooxygenase inhibition: is two better than one? , 2001, The Journal of rheumatology.

[10]  D. Faulkner,et al.  Phospholipase A2 inhibitors from marine organisms. , 1992, Journal of natural products.

[11]  M. d’Ischia,et al.  Reaction of polygodial with primary amines: an alternative explanation to the antifeedant activity1☆ , 1982 .

[12]  Ruben Abagyan,et al.  ICM—A new method for protein modeling and design: Applications to docking and structure prediction from the distorted native conformation , 1994, J. Comput. Chem..

[13]  L. Gomez‐Paloma,et al.  The inactivation of phospholipase A2 by scalaradial: a biomimetic study by electrospray mass spectrometry. , 2005, Rapid communications in mass spectrometry : RCM.

[14]  E. Dennis,et al.  The growing phospholipase A2 superfamily of signal transduction enzymes. , 1997, Trends in biochemical sciences.

[15]  R. Abagyan,et al.  Determinants of retinoid X receptor transcriptional antagonism. , 2004, Journal of medicinal chemistry.

[16]  M. Lehr Phospholipase A2 inhibitors in inflammation , 2001 .

[17]  L. Gomez‐Paloma,et al.  Chemistry and Biology of Anti-Inflammatory Marine Natural Products. Phospholipase A2 Inhibitors , 2005 .

[18]  R. Jacobs,et al.  Two-step inactivation of bee venom phospholipase A2 by scalaradial. , 1991, Biochemical pharmacology.

[19]  L. Marshall,et al.  Inactivation of human synovial fluid phospholipase A2 by the marine natural product, manoalide. , 1990, Biochemical pharmacology.

[20]  Claudio N. Cavasotto,et al.  Representing receptor flexibility in ligand docking through relevant normal modes. , 2005, Journal of the American Chemical Society.

[21]  Claudio N. Cavasotto,et al.  Protein flexibility in ligand docking and virtual screening to protein kinases. , 2004, Journal of molecular biology.

[22]  D. Faulkner,et al.  Chemical mechanism of inactivation of bee venom phospholipase A2 by the marine natural products manoalide, luffariellolide, and scalaradial , 1992 .

[23]  P. Gopalakrishnakone,et al.  Group IIA secretory phospholipase A2 stimulates exocytosis and neurotransmitter release in pheochromocytoma-12 cells and cultured rat hippocampal neurons , 2003, Neuroscience.

[24]  D. Wilton A continuous fluorescence displacement assay for the measurement of phospholipase A2 and other lipases that release long-chain fatty acids. , 1990, The Biochemical journal.

[25]  G. Cimino,et al.  12-epi-scalarin and 12-epi-deoxoscalarin, Sesterterpenes from the sponge Spongia nitens. , 1977, Journal of the Chemical Society. Perkin transactions 1.

[26]  K. Glaser,et al.  Manoalide: structure-activity studies and definition of the pharmacophore for phospholipase A2 inactivation. , 1989, Molecular pharmacology.

[27]  P. Kovanen,et al.  Phospholipase A(2) in vascular disease. , 2001, Circulation research.

[28]  Ruben Abagyan,et al.  Protein structure prediction by global energy optimization , 1997 .

[29]  Claudio N. Cavasotto,et al.  Conformational Sampling of Protein Flexibility in Generalized Coordinates: Application to Ligand Docking , 2005 .

[30]  J. Balsinde,et al.  Regulation and inhibition of phospholipase A2. , 1999, Annual review of pharmacology and toxicology.

[31]  L. Gomez‐Paloma,et al.  Further insights on the structural aspects of PLA(2) inhibition by gamma-hydroxybutenolide-containing natural products: a comparative study on petrosaspongiolides M-R. , 2004, Bioorganic & medicinal chemistry.

[32]  K. Glaser,et al.  Pharmacological characterization of the pseudopterosins: novel anti-inflammatory natural products isolated from the Caribbean soft coral, Pseudopterogorgia elisabethae. , 1998, Life sciences.

[33]  L. Gomez‐Paloma,et al.  Chemistry and biology of anti-inflammatory marine natural products: molecules interfering with cyclooxygenase, NF-kappaB and other unidentified targets. , 2006, Current medicinal chemistry.

[34]  W Pruzanski,et al.  Cloning and recombinant expression of phospholipase A2 present in rheumatoid arthritic synovial fluid. , 1989, The Journal of biological chemistry.

[35]  G. Marino,et al.  Molecular Basis of Phospholipase A2 Inhibition by Petrosaspongiolide M , 2002, Chembiochem : a European journal of chemical biology.

[36]  N. C. Price,et al.  The application of circular dichroism to studies of protein folding and unfolding. , 1997, Biochimica et biophysica acta.

[37]  S. de Rosa,et al.  A new scalarane sesterterpenoid from the marine sponge Cacospongia mollior. , 1994, Journal of Natural Products.

[38]  L. Marshall,et al.  Effects of scalaradial, a type II phospholipase A2 inhibitor, on human neutrophil arachidonic acid mobilization and lipid mediator formation. , 1994, The Journal of pharmacology and experimental therapeutics.

[39]  A. Kleinfeld,et al.  Continuous measurement of phospholipase A2 activity using the fluorescent probe ADIFAB. , 1995, Analytical biochemistry.

[40]  P. Vadas,et al.  Role of secretory phospholipases A2 in the pathobiology of disease. , 1986, Laboratory investigation; a journal of technical methods and pathology.

[41]  K. Glaser,et al.  Regulation of prostaglandin H synthase 2 expression in human monocytes by the marine natural products manoalide and scalaradial. Novel effects independent of inhibition of lipid mediator production. , 1995, Biochemical pharmacology.

[42]  D. Wilton,et al.  Comparison of the catalytic properties of phospholipase A2 from pancreas and venom using a continuous fluorescence displacement assay. , 1991, The Biochemical journal.

[43]  Claudio N. Cavasotto,et al.  Structure‐based identification of binding sites, native ligands and potential inhibitors for G‐protein coupled receptors , 2003, Proteins.